Keratoprosthesis in Autoimmune Disease

REFERENCES

• Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001:79:214–221.
   PubMed Web of Science ®Google Scholar
• Thompson RW Jr, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003:110:1396–1402.
   Google Scholar
• Sayegh RR, Ang LP, Foster CS, et al. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008:145:438–444.
   PubMed Web of Science ®Google Scholar
• Zerbe BL, Belin MW, Ciolino JB. Boston Type 1 Keratoprosthesis Study Group. Results from the multicenter Boston Type 1 Keratoprosthesis Study. Ophthalmology. 2006:113:1779.e1–e7.
   Google Scholar
• Aldave AJ, Kamal KM, Vo RC, et al. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009:116:640–651.
   PubMed Web of Science ®Google Scholar
• Bradley JC, Hernandez EG, Schwab IR, et al. Boston type I keratoprosthesis: the University of California Davis experience. Cornea. 2009:28:321–327.
   PubMed Web of Science ®Google Scholar
• Chew HF, Ayres BD, Hammersmith KM, et al. Boston keratoprosthesis outcomes and complications. Cornea. 2009 Aug 29 (epub ahead of print).
   Google Scholar
• Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001:20:19–23.
   PubMed Web of Science ®Google Scholar
• Dudenhoefer EJ, Nouri M, Gipson IK, et al. Histopathology of explanted collar button keratoprostheses: a clinicopathologic correlation. Cornea. 2003:22:424–428.
   PubMed Web of Science ®Google Scholar
• Stoiber J, Csaky D, Schedle A, et al. Histopathologic findings in explanted osteo-odontokeratoprosthesis. Cornea. 2002:21:400–404.
   PubMed Web of Science ®Google Scholar
• Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005:94:419–436.
   PubMed Web of Science ®Google Scholar
• Long M, Rack HJ. Titanium alloys in total joint replacement—a materials science perspective. Biomaterials. 1998:19:1621–1639.
   PubMed Web of Science ®Google Scholar
• Lloyd AW, Faragher RG, Denyer SP. Ocular biomaterials and implants. Biomaterials. 2001:22:769–785.
   PubMed Web of Science ®Google Scholar
• Lisowska B, Maslinski W, Maldyk P, et al. The role of cytokines in inflammatory response after total knee arthroplasty in patients with rheumatoid arthritis. Rhematol Int. 2008:28:667–671.
   Google Scholar
• Gualini F, Berglundh T. Immunohistochemical characteristics of inflammatory lesions at implants. J Clin Periodontol. 2003:30:14–18.
   PubMedGoogle Scholar
• Bullon P, Fioroni M, Goteri G, et al. Immunohistochemical analysis of soft tissues in implants with healthy and peri-implantitis condition, and aggressive periodontitis. Clin Oral Implants Res. 2004:15:553–559.
   Google Scholar
• Borsani E, Salgarello S, Stacchiotti A, et al. Altered immunolocalization of heat-shock proteins in human peri-implant gingiva. Acta Histochem. 2007:109:221–227.
   Google Scholar
• Konttinen YT, Lappalainen R, Laine P, et al. Immunohistochemical evaluation of inflammatory mediators in failing implants. Int J Periodontics Restorative Dent. 2006:26:135–141.
   Google Scholar
• Leung KC, McMillan AS, Cheung BP, et al. Sjögren’s syndrome sufferers have increased oral yeast levels despite regular dental care. Oral Dis. 2008:14:163–173.
   Google Scholar
• Nalepka JL, Lee MJ, Kraay MJ, et al. Lipopolysaccharide found in aseptic loosening of patients with inflammatory arthritis. Clin Orthop Relat Res. 2006:451:229–235.
   PubMedGoogle Scholar
• Engesaeter LB, Lie SA, Espehaug B, et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0–14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2003:74:644–651.
   PubMed Web of Science ®Google Scholar
• Chadha HS, Wooley PH, Sud S, et al. Cellular prolieferation and cytokine responses to polymethylmethacrylate particles in patients with a cemented total joint arthroplasty. Inflamm Res. 1995:44:145–151.
   Google Scholar
• Gil-Albarova J, Lacleriga A, Barrios C, et al. Lymphocyte response to polymethylmethacrylate in loose total hip prostheses. J Bone Joint Surg Br. 1992:74:825–830.
   PubMedGoogle Scholar
• Willert HG, Bertram H, Buchhorn GH. Osteolysis in alloarthroplasty of the hip: the role of bone cement fragmentation. Clin Orthop Relat Res. 1990:258:108–121.
   Google Scholar
• Toumbis CA, Kronick JL, Wooley PH, et al. Total joint arthroplasty and the immune response. Semin Arthritis Rheum. 1997:27:44–47.
   Google Scholar
• Letko E, Bhol K, Colon C, et al. Biology of interleukin-5 in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol. 2002:240:565–569.
   PubMedGoogle Scholar
• Lee SJ, Li Z, Sherman B, et al. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1993:34:3522–3525.
   PubMed Web of Science ®Google Scholar
• Kumari S, Bhol KC, Rehman F, et al. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Cytokine. 2001:14:218–224.
   Google Scholar
• Elder MJ, Dart JK, Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid—the role of cytokines. Exp Eye Res. 1997:65:165–176.
   PubMed Web of Science ®Google Scholar
• Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004:123:850–855.
   PubMedGoogle Scholar
• Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002:118:728–733.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000:47:85–118.
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009:28:117–144.
   PubMed Web of Science ®Google Scholar
• Dohlman JG, Foster CS, Dohlman CH. Boston Keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis. D J Ophthalmol. 2009:15:1–5.
   Google Scholar
• Gregory DG. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocul Surf. 2008:6:87–95.
   PubMed Web of Science ®Google Scholar
• Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008:6:128–142.
   PubMed Web of Science ®Google Scholar
• Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci. 2009:50:3346–3352.
   PubMed Web of Science ®Google Scholar
• Ament JD, Stryjewski TP, Ciolino JB, et al. Cost-effectiveness of the Boston keratoprosthesis. Am J Ophthalmol. 2009 Nov 23 (epub ahead of print).
   Google Scholar